R. Torrado

发表

Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate‐to‐severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm

M. Llamas-Velasco, I. García-Doval, J. Carrascosa, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry

F. Vanaclocha, I. García-Doval, J. Carrascosa, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5‐year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry

I. García-Doval, J. Carrascosa, I. Belinchón, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database

F. Vanaclocha, I. García-Doval, G. Carretero, 2015 .

Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database.

F. Vanaclocha, I. García-Doval, G. Carretero, 2015, Actas dermo-sifiliograficas.

Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry

F. Vanaclocha, I. García-Doval, J. Carrascosa, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

F. Vanaclocha, I. García-Doval, J. Carrascosa, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.

F. Vanaclocha, I. García-Doval, P. Dávila-Seijo, 2017, The Journal of investigative dermatology.

Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice

F. Vanaclocha, I. García-Doval, J. Carrascosa, 2015, The Journal of dermatological treatment.

Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis

F. Vanaclocha, I. García-Doval, P. Dávila-Seijo, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry.

F. Vanaclocha, M. Llamas-Velasco, J. Carrascosa, 2017, Actas dermo-sifiliograficas.

Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort

F. Vanaclocha, I. García-Doval, J. Carrascosa, 2016, The Journal of dermatological treatment.

Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

F. Vanaclocha, I. García-Doval, G. Carretero, 2014, Journal of the European Academy of Dermatology and Venereology.

Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts

F. Vanaclocha, I. García-Doval, R. Sanmartí, 2017, The British journal of dermatology.